

11 January 2012

Antisoma plc (“Antisoma” or the “Company”)

Admission to AIM

Further to its announcement on 7 December 2011, Antisoma is pleased to confirm that the admission to trading on AIM (“Admission”) of its ordinary shares of 1 pence each occurred at 8:00 a.m. today, 11 January 2011.

The Company also confirms that as at Admission it has been classified as an Investing Company (as defined in the AIM Rules for Companies). The Company’s Investing Policy, as approved by Antisoma shareholders at the Company’s general meeting on 7 December 2011, is summarised below:

The directors of Antisoma (the “Directors”) intend to identify investment opportunities offering the potential to deliver a favourable return to shareholders over the medium term, primarily in the form of a capital gain. A particular consideration will be to identify businesses which, in the opinion of the Directors, are under-performing and present opportunities for value creation. The Company’s equity interest in a potential investment may range from a minority position to 100 per cent. ownership and the interest may be either quoted or unquoted.

The Directors intend to be active investors and to assist in the strategic development and growth of significant acquisitions and/or investments made by the Company. The acquisitions or investments may be funded from existing cash resources, by the issue of new ordinary shares or with debt, or a combination thereof, as the Directors deem appropriate.

It is anticipated that returns to shareholders will be delivered principally through capital growth rather than capital distributions via dividends, although it may become appropriate to distribute funds to shareholders once the Company’s investments mature.

Disclosures on the Company as required by AIM Rule 26 can be found at: www.antisoma.com

Commenting on Admission, Mike Pappas, Chairman of Antisoma, said:

“We are delighted to have completed the move to AIM. We believe that the AIM market is more appropriate for the Company given its size and ongoing strategy and we look forward to implementing the Company’s Investing Policy.”

Enquiries:

Antisoma
Mike Bretherton

Tel: +44 (0) 20 7099 7268

Altium – NOMAD to Antisoma
Tim Richardson / Katherine Hobbs

Tel: +44 (0) 20 7484 4040

WH Ireland – Broker to Antisoma
Chris Fielding

Tel: +44 (0) 20 7220 1666